db087000-74fa-4044-812f-01842b99f448
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.570
- PROTEIN_SECRETION+0.450
- FATTY_ACID_METABOLISM+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- P53_PATHWAY+0.310
- PEROXISOME+0.290
- MYC_TARGETS_V1+0.280
- ADIPOGENESIS+0.260
- BILE_ACID_METABOLISM+0.260
- ESTROGEN_RESPONSE_LATE+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- MYOGENESIS-0.400
- ANGIOGENESIS-0.390
- APICAL_JUNCTION-0.290
- HEDGEHOG_SIGNALING-0.280
- MITOTIC_SPINDLE-0.260
- G2M_CHECKPOINT-0.240
- WNT_BETA_CATENIN_SIGNALING-0.230
- COAGULATION-0.220
- UV_RESPONSE_DN-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4769f22f-eeaf-4108-9555-55cc5d6ae27b | — | — | 0.862 |
| 2 | e59f49c0-d7ce-44c3-9590-9b65128d7f8b | — | — | 0.826 |
| 3 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.818 |
| 4 | c7aea5a2-5772-4475-8ca6-326193eeb69e | — | — | 0.816 |
| 5 | SRR27320676 | — | — | 0.815 |
| 6 | MNG510 | — | — | 0.791 |
| 7 | R149 | — | — | 0.787 |
| 8 | TCGA-CV-5439-01A-01R-1686-07 | — | — | 0.778 |
| 9 | SRR2016973 | — | — | 0.777 |
| 10 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.767 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |